Edition:
India

Allakos Inc (ALLK.OQ)

ALLK.OQ on NASDAQ Stock Exchange Global Select Market

87.37USD
20 Sep 2019
Change (% chg)

$4.67 (+5.65%)
Prev Close
$82.70
Open
$82.37
Day's High
$88.73
Day's Low
$82.00
Volume
633,599
Avg. Vol
171,145
52-wk High
$92.82
52-wk Low
$29.50

Latest Key Developments (Source: Significant Developments)

Allakos Inc Files For Potential Stock Shelf, Size Not Disclosed
Tuesday, 6 Aug 2019 

Aug 5 (Reuters) - Allakos Inc ::ALLAKOS INC - MAY OFFER AND SELL SHARES OF COMMON STOCK FROM TIME TO TIME.ALLAKOS INC - IN ADDITION, SELLING STOCKHOLDERS MAY OFFER AND SELL FROM TIME TO TIME AND IN ONE OR MORE OFFERINGS, SHARES OF COMMON STOCK.ALLAKOS INC FILES FOR POTENTIAL STOCK SHELF, SIZE NOT DISCLOSED - SEC FILING.  Full Article

Allakos Announces Proposed Public Offering Of Common Stock
Tuesday, 6 Aug 2019 

Aug 5 (Reuters) - Allakos Inc ::ALLAKOS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ALLAKOS INC - INTENDS TO OFFER AND SELL $200 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.ALLAKOS INC - CURRENTLY EXPECTS TO USE NET PROCEEDS FROM OFFERING FOR GENERAL CORPORATE PURPOSES.  Full Article

Allakos Says Appointed Leo Redmond As CFO
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Allakos Inc ::ALLAKOS INC - APPOINTED LEO REDMOND AS CHIEF FINANCIAL OFFICER OF COMPANY.ALLAKOS INC - REDMOND TO SUCCEED ADAM TOMASI.  Full Article

Allakos Q2 Loss Per Share $0.44
Monday, 5 Aug 2019 

Allakos Inc ::ALLAKOS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.44.Q2 EARNINGS PER SHARE ESTIMATE $-0.45 -- REFINITIV IBES DATA.ENDED Q2 OF 2019 WITH $153.1 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.  Full Article

Allakos Says Ak002 Met All Goals In Phase 2 Study In Patients With Eosinophilic Gastritis
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Allakos Inc ::ALLAKOS ANNOUNCES AK002 MET ALL PRESPECIFIED PRIMARY AND SECONDARY ENDPOINTS IN PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH EOSINOPHILIC GASTRITIS (EG) AND/OR EOSINOPHILIC GASTROENTERITIS (EGE).ALLAKOS INC - ALLAKOS PLANS TO INITIATE STUDIES IN EG/EGE AND EOE IN Q1 2020.ALLAKOS INC - PRIMARY EFFICACY ENDPOINT MET WITH 95% REDUCTION IN GASTROINTESTINAL TISSUE EOSINOPHILS VERSUS. 10% INCREASE ON PLACEBO.ALLAKOS INC - TREATMENT RESPONSE SECONDARY ENDPOINT MET WITH 69% OF AK002 TREATED PATIENTS MEETING RESPONSE CRITERIA VERSUS. 5% ON PLACEBO.ALLAKOS INC - TOTAL SYMPTOM SCORE SECONDARY ENDPOINT MET WITH 53% REDUCTION IN PATIENT REPORTED TOTAL SYMPTOM SCORE VERSUS. 24% ON PLACEBO.ALLAKOS INC - WILL REQUEST END OF PHASE 2 MEETING TO DISCUSS DESIGN OF PLANNED PHASE 3 STUDY IN EG AND/OR EGE AND PHASE 2/3 STUDY IN EOE.  Full Article

Allakos Reports Q1 Loss Per Share Of $0.47
Wednesday, 8 May 2019 

May 8 (Reuters) - Allakos Inc ::ALLAKOS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.47.ENDED Q1 OF 2019 WITH $167.2 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.  Full Article

Neurometrix Q2 Revenue Fell 13 Pct To $3.8 Million
Thursday, 19 Jul 2018 

July 19 (Reuters) - Neurometrix Inc ::NEUROMETRIX REPORTS Q2 2018 FINANCIAL RESULTS.Q2 REVENUE FELL 13 PERCENT TO $3.8 MILLION.ALLAKOS INC QUARTERLY NET INCOME OF $0.6 MILLION COMPARED WITH A NET LOSS OF $3.2 MILLION IN Q2 2017.EXPECTS TOTAL FUNDING FROM GLAXOSMITHKLINE STRATEGIC COLLABORATION DURING 2018 TO BE $12.7 MILLION.  Full Article